Yesterday, May 4, 2016, 86 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,916.49 to $4,828,179.42. Highlighted Stocks Traded by Insiders: Sunstone Hotel Investors (SHO) - FREE Research Report Sloan David Ryan, who is Former SVP- General Counsel at Sunstone Hotel Investors, sold 35,209 shares at $12.44 on May 4, 2016. Following this transaction, the Former SVP- General Counsel owned 0 shares meaning that the stake was reduced by 100% with the 35,209-share transaction. The shares most recently traded at $12.74, up $0.30, or 2.35% since the insider transaction. Historical insider transactions for Sunstone Hotel Investors go as follows:

  • 4-Week # shares bought: 17,750
  • 4-Week # shares sold: 38,070
  • 12-Week # shares bought: 17,750
  • 12-Week # shares sold: 38,070
  • 24-Week # shares bought: 17,750
  • 24-Week # shares sold: 38,070

The average volume for Sunstone Hotel Investors has been 2.3 million shares per day over the past 30 days. Sunstone Hotel Investors has a market cap of $2.7 billion and is part of the financial sector and real estate industry. Shares are up 1.68% year-to-date as of the close of trading on Wednesday. Sunstone Hotel Investors, Inc. operates as a real estate investment trust. The firm engages in the acquisition, ownership, asset management, renovation, and sale of luxury, upper upscale, and upscale full-service hotels in the United States. Its portfolio also includes mid-scale hotels. The stock currently has a dividend yield of 11.14%. The company has a P/E ratio of 8.2. Currently, there are 6 analysts who rate Sunstone Hotel Investors a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SHO - FREE

TheStreet Quant Ratings

rates Sunstone Hotel Investors as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, reasonable valuation levels and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Sunstone Hotel Investors Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Integra Lifesciences Holdings (IART) - FREE Research Report

Reuvers Daniel L., who is Corp VP, Pres. International at Integra Lifesciences Holdings, sold 1,000 shares at $71.43 on May 4, 2016. Following this transaction, the Corp VP, Pres. International owned 9,747 shares meaning that the stake was reduced by 9.3% with the 1,000-share transaction. The shares most recently traded at $70.97, down $0.46, or 0.65% since the insider transaction. Historical insider transactions for Integra Lifesciences Holdings go as follows:

  • 4-Week # shares sold: 5,500
  • 12-Week # shares sold: 5,500
  • 24-Week # shares sold: 5,500

The average volume for Integra Lifesciences Holdings has been 281,200 shares per day over the past 30 days. Integra Lifesciences Holdings has a market cap of $2.6 billion and is part of the health care sector and health services industry. Shares are up 3.98% year-to-date as of the close of trading on Wednesday. Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has a P/E ratio of 469.5. Currently, there are 7 analysts who rate Integra Lifesciences Holdings a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IART - FREE

TheStreet Quant Ratings

rates Integra Lifesciences Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, robust revenue growth, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Integra Lifesciences Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

T-Mobile US (TMUS) - FREE Research Report

Myers Larry L, who is EVP, Human Resources at T-Mobile US, sold 3,000 shares at $39.51 on May 4, 2016. Following this transaction, the EVP, Human Resources owned 136,260 shares meaning that the stake was reduced by 2.15% with the 3,000-share transaction. Miller David A, who is EVP, General Counsel & Sec. at T-Mobile US, sold 5,000 shares at $40.00 on May 4, 2016. Following this transaction, the EVP, General Counsel & Sec. owned 129,816 shares meaning that the stake was reduced by 3.71% with the 5,000-share transaction. The shares most recently traded at $39.58, down $0.42, or 1.06% since the insider transaction. Historical insider transactions for T-Mobile US go as follows:

  • 4-Week # shares sold: 11,906
  • 12-Week # shares sold: 17,906
  • 24-Week # shares sold: 60,711

The average volume for T-Mobile US has been 4.9 million shares per day over the past 30 days. T-Mobile US has a market cap of $32.6 billion and is part of the technology sector and telecommunications industry. Shares are down 0.05% year-to-date as of the close of trading on Wednesday. T-Mobile US, Inc., together with its subsidiaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. The company has a P/E ratio of 27.0. Currently, there are 15 analysts who rate T-Mobile US a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TMUS - FREE

TheStreet Quant Ratings

rates T-Mobile US as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

T-Mobile US Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.